This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor: I would like to reply to the letter from Dr. Andrew Ageloff, Chief Resident in Pediatrics, Rochester General Hospital, on page 313 of your March issue, vol 105, No. 3.
It distresses me to see that Dr. Ageloff condemns the use of corticotropin (ACTH) in the treatment of jaundice of prematurity because of the infection which has occurred in his unit. I gave corticotropin to more than 100 infants in Marston Green Premature Baby Unit (near Birmingham), England, during 1959 and 1960 and found no increase in the existing low infection rate. Since 1961, Dr. Eileen Hill has been in charge of the unit and has continued to experiment with corticotropin in the treatment of jaundice of prematurity. When I saw her last August, she had had no trouble with infection. As the result of her work, she has reduced the dosage which I used in the
CROSSE VM. REPLY TO LETTER FROM DR. ANDREW AGELOFF. Am J Dis Child. 1963;106(1):116. doi:10.1001/archpedi.1963.02080050118018
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.